APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Fluid Biopsy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Tumor Fluid Biopsy Market Analysis and Forecast 2026-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchTumor Fluid Biopsy Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Fluid Biopsy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Tumor Fluid Biopsy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Fluid Biopsy Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Fluid Biopsy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Tumor Fluid Biopsy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Tumor Fluid Biopsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Tumor Fluid Biopsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Tumor Fluid Biopsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Tumor Fluid Biopsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Tumor Fluid Biopsy include Cellmax Life, Exact Science, Amoy Diagnostics Co, Berry Genomics Co, Genetronhealth, GenoploRare, HaploX Biotechnology Co, New Horizon Health Limited and Burning Rock Biotech, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Tumor Fluid Biopsy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Tumor Fluid Biopsy, also provides the revenue of main regions and countries. Of the upcoming market potential for Tumor Fluid Biopsy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tumor Fluid Biopsy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tumor Fluid Biopsy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Tumor Fluid Biopsy revenue, projected growth trends, production technology, application and end-user industry.

Tumor Fluid Biopsy Segment by Company

Cellmax Life

Exact Science

Amoy Diagnostics Co

Berry Genomics Co

Genetronhealth

GenoploRare

HaploX Biotechnology Co

New Horizon Health Limited

Burning Rock Biotech

Guangzhou Wondfo Biotech

YZY Biopharma

Tumor Fluid Biopsy Segment by Type

CTDNA Detection

CTC Detection

Other

Tumor Fluid Biopsy Segment by Application

Hospital

Third Party Organization

Other

Tumor Fluid Biopsy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Fluid Biopsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Fluid Biopsy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Fluid Biopsy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Tumor Fluid Biopsy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Tumor Fluid Biopsy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Fluid Biopsy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumor Fluid Biopsy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CTDNA Detection Major Player Table 3. CTC Detection Major Player Table 4. Other Major Player Table 5. Global Tumor Fluid Biopsy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Third Party Organization Major Player Table 8. Other Major Player Table 9. Tumor Fluid Biopsy Industry Trends Table 10. Tumor Fluid Biopsy Industry Drivers Table 11. Tumor Fluid Biopsy Industry Opportunities and Challenges Table 12. Tumor Fluid Biopsy Industry Restraints Table 13. Global Tumor Fluid Biopsy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Tumor Fluid Biopsy Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Tumor Fluid Biopsy Market Share by Region (2021-2026) Table 16. Global Tumor Fluid Biopsy Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Tumor Fluid Biopsy Market Share by Region (2027-2032) Table 18. Global Tumor Fluid Biopsy Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Tumor Fluid Biopsy Revenue Market Share by Players (2021-2026) Table 20. Global Tumor Fluid Biopsy Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Tumor Fluid Biopsy Key Players Headquarters & Area Served Table 22. Global Tumor Fluid Biopsy Players, Product Type & Application Table 23. Global Tumor Fluid Biopsy Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Tumor Fluid Biopsy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Tumor Fluid Biopsy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Tumor Fluid Biopsy Revenue Market Share by Type (2021-2026) Table 30. Global Tumor Fluid Biopsy Revenue Market Share by Type (2027-2032) Table 31. Global Tumor Fluid Biopsy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Tumor Fluid Biopsy Revenue Market Share by Application (2021-2026) Table 35. Global Tumor Fluid Biopsy Revenue Market Share by Application (2027-2032) Table 36. Cellmax Life Company Information Table 37. Cellmax Life Business Overview Table 38. Cellmax Life Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Cellmax Life Tumor Fluid Biopsy Product Portfolio Table 40. Cellmax Life Recent Development Table 41. Exact Science Company Information Table 42. Exact Science Business Overview Table 43. Exact Science Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Exact Science Tumor Fluid Biopsy Product Portfolio Table 45. Exact Science Recent Development Table 46. Amoy Diagnostics Co Company Information Table 47. Amoy Diagnostics Co Business Overview Table 48. Amoy Diagnostics Co Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Amoy Diagnostics Co Tumor Fluid Biopsy Product Portfolio Table 50. Amoy Diagnostics Co Recent Development Table 51. Berry Genomics Co Company Information Table 52. Berry Genomics Co Business Overview Table 53. Berry Genomics Co Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Berry Genomics Co Tumor Fluid Biopsy Product Portfolio Table 55. Berry Genomics Co Recent Development Table 56. Genetronhealth Company Information Table 57. Genetronhealth Business Overview Table 58. Genetronhealth Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Genetronhealth Tumor Fluid Biopsy Product Portfolio Table 60. Genetronhealth Recent Development Table 61. GenoploRare Company Information Table 62. GenoploRare Business Overview Table 63. GenoploRare Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. GenoploRare Tumor Fluid Biopsy Product Portfolio Table 65. GenoploRare Recent Development Table 66. HaploX Biotechnology Co Company Information Table 67. HaploX Biotechnology Co Business Overview Table 68. HaploX Biotechnology Co Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. HaploX Biotechnology Co Tumor Fluid Biopsy Product Portfolio Table 70. HaploX Biotechnology Co Recent Development Table 71. New Horizon Health Limited Company Information Table 72. New Horizon Health Limited Business Overview Table 73. New Horizon Health Limited Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. New Horizon Health Limited Tumor Fluid Biopsy Product Portfolio Table 75. New Horizon Health Limited Recent Development Table 76. Burning Rock Biotech Company Information Table 77. Burning Rock Biotech Business Overview Table 78. Burning Rock Biotech Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Burning Rock Biotech Tumor Fluid Biopsy Product Portfolio Table 80. Burning Rock Biotech Recent Development Table 81. Guangzhou Wondfo Biotech Company Information Table 82. Guangzhou Wondfo Biotech Business Overview Table 83. Guangzhou Wondfo Biotech Tumor Fluid Biopsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Guangzhou Wondfo Biotech Tumor Fluid Biopsy Product Portfolio Table 85. Guangzhou Wondfo Biotech Recent Development Table 86. YZY Biopharma Company Information Table 87. YZY Biopharma Business Overview Table 88. YZY Biopharma Tumor Fluid Biopsy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. YZY Biopharma Tumor Fluid Biopsy Product Portfolio Table 90. YZY Biopharma Recent Development Table 91. North America Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Tumor Fluid Biopsy Revenue by Country (2021-2026) & (US$ Million) Table 97. North America Tumor Fluid Biopsy Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Tumor Fluid Biopsy Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe Tumor Fluid Biopsy Revenue by Country (US$ Million) & (2027-2032) Table 105. China Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 106. China Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 107. China Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 108. China Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Tumor Fluid Biopsy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Tumor Fluid Biopsy Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia Tumor Fluid Biopsy Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA Tumor Fluid Biopsy Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA Tumor Fluid Biopsy Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA Tumor Fluid Biopsy Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA Tumor Fluid Biopsy Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA Tumor Fluid Biopsy Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA Tumor Fluid Biopsy Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Tumor Fluid Biopsy Image Figure 2. Global Tumor Fluid Biopsy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Fluid Biopsy Market Size Share 2021 VS 2025 VS 2032 Figure 4. CTDNA Detection Image Figure 5. CTC Detection Image Figure 6. Other Image Figure 7. Global Tumor Fluid Biopsy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Tumor Fluid Biopsy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Third Party Organization Image Figure 11. Other Image Figure 12. Global Tumor Fluid Biopsy Market Size (US$ Million) & (2021-2032) Figure 13. Global Tumor Fluid Biopsy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Tumor Fluid Biopsy Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Tumor Fluid Biopsy Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Tumor Fluid Biopsy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tumor Fluid Biopsy Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Tumor Fluid Biopsy Revenue Market Share by Type (2021-2032) Figure 20. Global Tumor Fluid Biopsy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Tumor Fluid Biopsy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Tumor Fluid Biopsy Revenue Market Share by Application (2021-2032) Figure 23. North America Tumor Fluid Biopsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Tumor Fluid Biopsy Revenue Share by Type (2021-2032) Figure 25. North America Tumor Fluid Biopsy Revenue Share by Application (2021-2032) Figure 26. North America Tumor Fluid Biopsy Revenue Share by Country (2021-2032) Figure 27. United States Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Tumor Fluid Biopsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Tumor Fluid Biopsy Revenue Share by Type (2021-2032) Figure 32. Europe Tumor Fluid Biopsy Revenue Share by Application (2021-2032) Figure 33. Europe Tumor Fluid Biopsy Revenue Share by Country (2021-2032) Figure 34. Germany Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Tumor Fluid Biopsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Tumor Fluid Biopsy Revenue Share by Type (2021-2032) Figure 44. China Tumor Fluid Biopsy Revenue Share by Application (2021-2032) Figure 45. Asia Tumor Fluid Biopsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Tumor Fluid Biopsy Revenue Share by Type (2021-2032) Figure 47. Asia Tumor Fluid Biopsy Revenue Share by Application (2021-2032) Figure 48. Asia Tumor Fluid Biopsy Revenue Share by Region (2021-2032) Figure 49. Japan Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Tumor Fluid Biopsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Tumor Fluid Biopsy Revenue Share by Type (2021-2032) Figure 57. SAMEA Tumor Fluid Biopsy Revenue Share by Application (2021-2032) Figure 58. SAMEA Tumor Fluid Biopsy Revenue Share by Country (2021-2032) Figure 59. Brazil Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Tumor Fluid Biopsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • CTDNA Detection
  • CTC Detection
  • Other
Applications
  • Hospital
  • Third Party Organization
  • Other
Companies covered
  • Cellmax Life
  • Exact Science
  • Amoy Diagnostics Co
  • Berry Genomics Co
  • Genetronhealth
  • GenoploRare
  • HaploX Biotechnology Co
  • New Horizon Health Limited
  • Burning Rock Biotech
  • Guangzhou Wondfo Biotech
  • YZY Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Tumor Fluid Biopsy Market by Type
  3. 1.2.1 Global Tumor Fluid Biopsy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CTDNA Detection
  5. 1.2.3 CTC Detection
  6. 1.2.4 Other
  7. 1.3 Tumor Fluid Biopsy Market by Application
  8. 1.3.1 Global Tumor Fluid Biopsy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Third Party Organization
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Tumor Fluid Biopsy Market Dynamics
  1. 2.1 Tumor Fluid Biopsy Industry Trends
  2. 2.2 Tumor Fluid Biopsy Industry Drivers
  3. 2.3 Tumor Fluid Biopsy Industry Opportunities and Challenges
  4. 2.4 Tumor Fluid Biopsy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Tumor Fluid Biopsy Market Perspective (2021-2032)
  2. 3.2 Global Tumor Fluid Biopsy Growth Trends by Region
  3. 3.2.1 Global Tumor Fluid Biopsy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Tumor Fluid Biopsy Market Size by Region (2021-2026)
  5. 3.2.3 Global Tumor Fluid Biopsy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Tumor Fluid Biopsy Revenue by Players
  2. 4.1.1 Global Tumor Fluid Biopsy Revenue by Players (2021-2026)
  3. 4.1.2 Global Tumor Fluid Biopsy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Tumor Fluid Biopsy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Tumor Fluid Biopsy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Tumor Fluid Biopsy Key Players Headquarters & Area Served
  7. 4.4 Global Tumor Fluid Biopsy Players, Product Type & Application
  8. 4.5 Global Tumor Fluid Biopsy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Tumor Fluid Biopsy Market CR5 and HHI
  11. 4.6.3 2025 Tumor Fluid Biopsy Tier 1, Tier 2, and Tier 3
5 Tumor Fluid Biopsy Market Size by Type
  1. 5.1 Global Tumor Fluid Biopsy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 5.3 Global Tumor Fluid Biopsy Revenue Market Share by Type (2021-2032)
6 Tumor Fluid Biopsy Market Size by Application
  1. 6.1 Global Tumor Fluid Biopsy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Tumor Fluid Biopsy Revenue by Application (2021-2032)
  3. 6.3 Global Tumor Fluid Biopsy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cellmax Life
  2. 7.1.1 Cellmax Life Company Information
  3. 7.1.2 Cellmax Life Business Overview
  4. 7.1.3 Cellmax Life Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cellmax Life Tumor Fluid Biopsy Product Portfolio
  6. 7.1.5 Cellmax Life Recent Developments
  7. 7.2 Exact Science
  8. 7.2.1 Exact Science Company Information
  9. 7.2.2 Exact Science Business Overview
  10. 7.2.3 Exact Science Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Exact Science Tumor Fluid Biopsy Product Portfolio
  12. 7.2.5 Exact Science Recent Developments
  13. 7.3 Amoy Diagnostics Co
  14. 7.3.1 Amoy Diagnostics Co Company Information
  15. 7.3.2 Amoy Diagnostics Co Business Overview
  16. 7.3.3 Amoy Diagnostics Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amoy Diagnostics Co Tumor Fluid Biopsy Product Portfolio
  18. 7.3.5 Amoy Diagnostics Co Recent Developments
  19. 7.4 Berry Genomics Co
  20. 7.4.1 Berry Genomics Co Company Information
  21. 7.4.2 Berry Genomics Co Business Overview
  22. 7.4.3 Berry Genomics Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Berry Genomics Co Tumor Fluid Biopsy Product Portfolio
  24. 7.4.5 Berry Genomics Co Recent Developments
  25. 7.5 Genetronhealth
  26. 7.5.1 Genetronhealth Company Information
  27. 7.5.2 Genetronhealth Business Overview
  28. 7.5.3 Genetronhealth Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genetronhealth Tumor Fluid Biopsy Product Portfolio
  30. 7.5.5 Genetronhealth Recent Developments
  31. 7.6 GenoploRare
  32. 7.6.1 GenoploRare Company Information
  33. 7.6.2 GenoploRare Business Overview
  34. 7.6.3 GenoploRare Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GenoploRare Tumor Fluid Biopsy Product Portfolio
  36. 7.6.5 GenoploRare Recent Developments
  37. 7.7 HaploX Biotechnology Co
  38. 7.7.1 HaploX Biotechnology Co Company Information
  39. 7.7.2 HaploX Biotechnology Co Business Overview
  40. 7.7.3 HaploX Biotechnology Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 HaploX Biotechnology Co Tumor Fluid Biopsy Product Portfolio
  42. 7.7.5 HaploX Biotechnology Co Recent Developments
  43. 7.8 New Horizon Health Limited
  44. 7.8.1 New Horizon Health Limited Company Information
  45. 7.8.2 New Horizon Health Limited Business Overview
  46. 7.8.3 New Horizon Health Limited Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 New Horizon Health Limited Tumor Fluid Biopsy Product Portfolio
  48. 7.8.5 New Horizon Health Limited Recent Developments
  49. 7.9 Burning Rock Biotech
  50. 7.9.1 Burning Rock Biotech Company Information
  51. 7.9.2 Burning Rock Biotech Business Overview
  52. 7.9.3 Burning Rock Biotech Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Burning Rock Biotech Tumor Fluid Biopsy Product Portfolio
  54. 7.9.5 Burning Rock Biotech Recent Developments
  55. 7.10 Guangzhou Wondfo Biotech
  56. 7.10.1 Guangzhou Wondfo Biotech Company Information
  57. 7.10.2 Guangzhou Wondfo Biotech Business Overview
  58. 7.10.3 Guangzhou Wondfo Biotech Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Guangzhou Wondfo Biotech Tumor Fluid Biopsy Product Portfolio
  60. 7.10.5 Guangzhou Wondfo Biotech Recent Developments
  61. 7.11 YZY Biopharma
  62. 7.11.1 YZY Biopharma Company Information
  63. 7.11.2 YZY Biopharma Business Overview
  64. 7.11.3 YZY Biopharma Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 YZY Biopharma Tumor Fluid Biopsy Product Portfolio
  66. 7.11.5 YZY Biopharma Recent Developments
8 North America
  1. 8.1 North America Tumor Fluid Biopsy Revenue (2021-2032)
  2. 8.2 North America Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 8.2.1 North America Tumor Fluid Biopsy Revenue by Type (2021-2026)
  4. 8.2.2 North America Tumor Fluid Biopsy Revenue by Type (2027-2032)
  5. 8.3 North America Tumor Fluid Biopsy Revenue Share by Type (2021-2032)
  6. 8.4 North America Tumor Fluid Biopsy Revenue by Application (2021-2032)
  7. 8.4.1 North America Tumor Fluid Biopsy Revenue by Application (2021-2026)
  8. 8.4.2 North America Tumor Fluid Biopsy Revenue by Application (2027-2032)
  9. 8.5 North America Tumor Fluid Biopsy Revenue Share by Application (2021-2032)
  10. 8.6 North America Tumor Fluid Biopsy Revenue by Country
  11. 8.6.1 North America Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Tumor Fluid Biopsy Revenue by Country (2021-2026)
  13. 8.6.3 North America Tumor Fluid Biopsy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Tumor Fluid Biopsy Revenue (2021-2032)
  2. 9.2 Europe Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Tumor Fluid Biopsy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Tumor Fluid Biopsy Revenue by Type (2027-2032)
  5. 9.3 Europe Tumor Fluid Biopsy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Tumor Fluid Biopsy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Tumor Fluid Biopsy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Tumor Fluid Biopsy Revenue by Application (2027-2032)
  9. 9.5 Europe Tumor Fluid Biopsy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Tumor Fluid Biopsy Revenue by Country
  11. 9.6.1 Europe Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Tumor Fluid Biopsy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Tumor Fluid Biopsy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Tumor Fluid Biopsy Revenue (2021-2032)
  2. 10.2 China Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 10.2.1 China Tumor Fluid Biopsy Revenue by Type (2021-2026)
  4. 10.2.2 China Tumor Fluid Biopsy Revenue by Type (2027-2032)
  5. 10.3 China Tumor Fluid Biopsy Revenue Share by Type (2021-2032)
  6. 10.4 China Tumor Fluid Biopsy Revenue by Application (2021-2032)
  7. 10.4.1 China Tumor Fluid Biopsy Revenue by Application (2021-2026)
  8. 10.4.2 China Tumor Fluid Biopsy Revenue by Application (2027-2032)
  9. 10.5 China Tumor Fluid Biopsy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Tumor Fluid Biopsy Revenue (2021-2032)
  2. 11.2 Asia Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Tumor Fluid Biopsy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Tumor Fluid Biopsy Revenue by Type (2027-2032)
  5. 11.3 Asia Tumor Fluid Biopsy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Tumor Fluid Biopsy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Tumor Fluid Biopsy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Tumor Fluid Biopsy Revenue by Application (2027-2032)
  9. 11.5 Asia Tumor Fluid Biopsy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Tumor Fluid Biopsy Revenue by Country
  11. 11.6.1 Asia Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Tumor Fluid Biopsy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Tumor Fluid Biopsy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Tumor Fluid Biopsy Revenue (2021-2032)
  2. 12.2 SAMEA Tumor Fluid Biopsy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Tumor Fluid Biopsy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Tumor Fluid Biopsy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Tumor Fluid Biopsy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Tumor Fluid Biopsy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Tumor Fluid Biopsy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Tumor Fluid Biopsy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Tumor Fluid Biopsy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Tumor Fluid Biopsy Revenue by Country
  11. 12.6.1 SAMEA Tumor Fluid Biopsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Tumor Fluid Biopsy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Tumor Fluid Biopsy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst